Novartis AG

Type: Company
Name: Novartis AG
Nationality: Switzerland
Web Address: http://www.novartis.com
Fact Sheet: Fact Sheet for Novartis India Ltd
First reported 59 mins ago - Updated 59 mins ago - 1 reports

NOVARTIS : reports 3,878 suspected cases of drug side effects

Novartis Pharma K.K . said Wednesday that it suspects a total of 3,878 cases of severe side effects related to drugs sold by the company after discovering documents on around 10,000 cases were left unattended.To examine the causal relationships between ... [Published 4 Traders - 59 mins ago]
First reported 1 hour ago - Updated 1 hour ago - 4 reports

Enanta Pharmaceuticals : Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research anddevelopment-focused biotechnology company dedicated to creating smallmolecule drugs in the infectious disease field, today announced that thecompany has entered into an agreement to regain full ... [Published 4 Traders - 1 hour ago]
First reported 1 hour ago - Updated 1 hour ago - 2 reports

Novartis announces Skin Impressions campaign launch on the first International

Urticaria Day, to provide support to people living with severe skin diseases such as chronic idiopathic urticaria (CIU)10/01 07:00 CDT Urticaria Day, to provide support to people living with severe skin diseases such as chronic idiopathic urticaria ... [Published Finwin - 1 hour ago]
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Novartis AG (NVS) Showing Resistance Near $94.90

Novartis AG (NVS) presents a trading opportunity that offers a 2.18% return in just 108 days.A covered call on Novartis AG at the $92.50 level expiring on Jan. '15 offers an assigned return rate of 2.18% or 7.35% annualized. This trade offers 3.82% downside ... [Published MarketIntelligenceCenter.com - 1 hour ago]
Entities: Novartis AG
First reported 19 hours ago - Updated 1 hour ago - 3 reports

Mealey's PI/Product Liability - Novartis Kickback Lawsuit Largely Survives Dismissal

NEW YORK - A New York federal judge on Sept. 30 largely denied a motion by Novartis Pharmaceuticals Corp. to dismiss a False Claims/Anti-Kickback lawsuit in which a whistle-blower, the federal government and New York State allege that the drug maker paid ... [Published Mealey - 1 hour ago]
First reported 8 hours ago - Updated 3 hours ago - 4 reports

Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014 »

New data for the IL-17A inhibitor AIN457 (secukinumab) in psoriasis and Xolair® in Chronic Spontaneous Urticaria (CSU) at EADV to highlight benefit to patients' quality of lifeData continue to reinforce the landmark Phase III results of secukinumab in ... [Published Noodls - 7 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Novartis showcases dermatology leadership on In...

The digital press release with multimedia content can be accessed here ... [Published MoneyAM - 8 hours ago]
First reported Sep 29 2014 - Updated Sep 30 2014 - 3 reports

Novartis receives CHMP recommendation for Signifor in acromegaly

:11 in Pharmaceutical Company Product News Novartis has announced that its Signifor long-acting release (LAR) formulation has been recommended for European approval for treating a rare hormonal disorder. The Committee for Medicinal Products for Human ... [Published Zenopa - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 2 reports

FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair

It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis ($NVS) and Roche ($RHHBY). Now the agency is taking action, slapping ... [Published FiercePharma - Sep 29 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

3 Pharmaceutical Giants on the Road to Curing Cancer

Cancer is a worldwide public health crisis. In the United States alone, one in four deaths is attributed to cancer, according to the American Cancer Society. But we are indeed slowly winning the war against cancer thanks to a combination of factors including ... [Published Healthcare Global - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 3 reports

Commission to consider consumer pharmaceuticals merger

The Commerce Commission has received an application from GlaxoSmithKline plc (GSK) seeking clearance to acquire Novartis AG’s consumer healthcare pharmaceutical business. ... [Published Scoop NZ - Business - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 5 reports

Research and Markets: Global Therapeutic Vaccines Market Outlook 2019 Featuring GSK, Merck, Novartis, Pfizer, Sanofi Avnetis & Serum Institute

Research and Markets ( http://www.researchandmarkets.com/research/9vl7kz/global ) has announced the addition of the "Global Therapeutic Vaccines Market- Trends And Forecasts (2014-2019)" report to their offering.Click to Continue » ... [Published Fort Mills Times - Sep 29 2014]

Quotes

Reinhard Dummer, of the University of Zurich Hospital, Switzerland, said: "Patients with NRAS mutations have no targeted treatment available and prognosis is poor. These data reinforce our view that binimetinib is an important new potential treatment option for these patients and I look forward to seeing the results from the ongoing Phase III NEMO trial to validate these findings."
...stakeholders becomes even more important," said Russell Libby, Sysco's executive vice president, corporate affairs and chief legal officer. "Nehl's breadth of experience in both communications and government relations will help us build, strengthen and execute an integrated strategy across Sysco that will enhance our industry leadership position and our ability to differentiate ourselves in the marketplace. We are excited to have Nehl join the Sysco team."
"We deeply apologize for causing great worry to patients and trouble to medical experts because of a delay in reporting side effects, which is extremely important for a pharmaceutical company" Novartis said in a statement
...idiopathic urticaria (CIU) for years now and speaks about the difficulties associated with her condition and the reaction she gets from others: "Our skin plays a key role in day-to-day human interactions, whether it's a first impression, handshake or hug. I once had to go to the ER because of a severe urticaria crisis and people were scared of me, moving away from me, thinking I was contagious. Seeing this kind of reaction from people is devastating. We must educate and inform to change misconceptions surrounding severe skin conditions. Uncover and re-examine how we view people living with skin diseases. Everyone should feel comfortable in their skin."

More Content

All (2942) | News (2135) | Reports (0) | Blogs (730) | Audio/Video (6) | Fact Sheets (32) | Press Releases (28)
sort by: Date | Relevance
Antidiarrheal Drugs Market: Global Industry Ana... [Published MyNewsDesk - 35 mins ago]
ESMO 2014: Boehringer Ingelheim’s new data for ... [Published Pharma Letter - 50 mins ago]
Nehl Horton Joins Sysco as Senior Vice Presiden... [Published Wall Street Select - 53 mins ago]
Nehl Horton Joins Sysco as Senior Vice Presiden... [Published Fat Pitch Financials - 53 mins ago]
NOVARTIS : reports 3,878 suspected cases of dru... [Published 4 Traders - 59 mins ago]
Enanta Pharmaceuticals : Regains Full Rights to... [Published 4 Traders - 1 hour ago]
Novartis announces Skin Impressions campaign la... [Published Finwin - 1 hour ago]
Alnylam Initiates EXPLORE, a Prospective Observ... [Published BusinessWeek - 1 hour ago]
Enanta Regains Full Rights to NS5A Inhibitor ED... [Published EON Science - 1 hour ago]
Novartis announces Skin Impressions campaign la... [Published PR Newswire: Health - 1 hour ago]
Novartis AG (NVS) Showing Resistance Near $94.90 [Published MarketIntelligenceCenter.com - 1 hour ago]
Enanta Regains Full Rights to NS5A Inhibitor ED... [Published Business Wire Science: Science News - 1 hour ago]
Enanta Regains Full Rights to NS5A Inhibitor ED... [Published Business Wire Health News - 1 hour ago]
Novartis reports positive data from Zykadia lun... [Published Zenopa - 1 hour ago]
Mealey's PI/Product Liability - Novartis Kickba... [Published Mealey - 1 hour ago]
Cambridge, UK – 29th September 2014 [Published Live-PR.com - 2 hours ago]
St. Joseph's Hospital Health Center Receives CE... [Published 4 Traders - 2 hours ago]
Dollars for Doctors: First Dive In to the New O... [Published Money Life - 6 hours ago]
ATTEMPT TO WEAKEN NPPA [Published PharmaBiz - 6 hours ago]
Biotech Boom On Third Coast Proves Everything's... [Published BioSpace - 7 hours ago]
Novartis showcases dermatology leadership on In... [Published Noodls - 7 hours ago]
Novartis showcases dermatology leadership on In... [Published ACN Newswire - 7 hours ago]
Novartis: 15 Abstracts From Specialty Dermatolo... [Published RTTNews.com - 7 hours ago]
Novartis showcases dermatology leadership on In... [Published MoneyAM - 8 hours ago]
Novartis Reports Results on Overall Survival fr... [Published Individual.com - 8 hours ago]
Novartis showcases dermatology leadership on In... [Published Nasdaq - 8 hours ago]
ANALYSIS-Plant-based vaccines challenge big pha... [Published CNBC - 8 hours ago]
The Global Awards Launches the Young Globals St... [Published ShootOnline - 10 hours ago]
GOP Nightmare Reveals Secret Corporate Donors [Published Creators.Com - 11 hours ago]
Our First Dive Into the New Open Payments System [Published ProPublica: Articles and Investigations - 11 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Enanta Regains Full Rights to NS5A Inhibitor ED... [Published EON Science - 1 hour ago]
WATERTOWN, Mass.--(EON: Enhanced Online News)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the company ...
Novartis announces Skin Impressions campaign la... [Published PR Newswire: Health - 1 hour ago]
Today is the first ever International Urticaria Day, an international event to increase urticaria awareness and improve care around the globe and let people living with urticaria know they are not aloneSkin Impressions campaign aims to break down barriers ...
Novartis AG (NVS) Showing Resistance Near $94.90 [Published MarketIntelligenceCenter.com - 1 hour ago]
Novartis AG (NVS) presents a trading opportunity that offers a 2.18% return in just 108 days.A covered call on Novartis AG at the $92.50 level expiring on Jan. '15 offers an assigned return rate of 2.18% or 7.35% annualized. This trade offers 3.82% downside ...
Enanta Regains Full Rights to NS5A Inhibitor ED... [Published Business Wire Science: Science News - 1 hour ago]
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the company has entered ...
Enanta Regains Full Rights to NS5A Inhibitor ED... [Published Business Wire Health News - 1 hour ago]
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the company has entered ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Lackluster Day On Wall Street Equals A Mixed Close [Published Wall Street Journal What's News - Jul 15 2014]
TECH PM -- Google and Novartis Team Up [Published Wall Street Journal Tech News Briefing - Jul 15 2014]
Big pharma braces for M&A wave [Published Reuters Video: Business - Apr 22 2014]
Novartis And GlaxoSmithKline Doing Deals [Published Wall Street Journal What's News - Apr 22 2014]
Novartis CEO: Revamp leaves us "fighting fit" [Published Reuters Video: Top News - Apr 22 2014]
1 2

Press Releases

sort by: Date | Relevance
Upcoming Presentations, Technical Update, Study... [Published Financial Services - Sep 05 2014]
Pharma Equities Technical Analysis -- Sanofi, A... [Published Financial Services - Aug 26 2014]
Global Hormone Replacement Therapy Market 2014-... [Published GlobeNewswire: Advertising News - Aug 20 2014]
Gamida Cell Announces Investment and Option Agr... [Published Financial Services - Aug 19 2014]
Technical Updates, Study Outcomes, Project Appr... [Published Financial Services - Aug 15 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.